USP30 alleviates intestinal ischemia-reperfusion injury by deubiquitinating MFN2 mediating the mitochondrial

Ziyi Weng1, Tulanisa Kadier1, Ruili Ding1

  • 1Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.

PubMed

Insights

Ubiquitin-specific peptidase 30 (USP30) protects against intestinal ischemia-reperfusion (IIR) injury by stabilizing Mitofusin 2 (MFN2). This action mitigates mitochondrial and endoplasmic reticulum damage, offering a potential therapeutic strategy for IIR.

Area of Science:

  • Cell Biology
  • Gastroenterology
  • Pathophysiology

Background:

  • Intestinal ischemia-reperfusion (IIR) injury leads to significant intestinal barrier damage, systemic inflammation, and mortality.
  • Mitochondrial-endoplasmic reticulum network disorder is a key mechanism in IIR.
  • Ubiquitin-specific peptidase 30 (USP30) and Mitofusin 2 (MFN2) are crucial for mitochondrial function and endoplasmic reticulum stress regulation.

Purpose of the Study:

  • To investigate the role of USP30 and MFN2 in IIR.
  • To elucidate the mechanism by which USP30 influences MFN2 stability and alleviates IIR.
  • To explore USP30 as a potential therapeutic target for IIR.

Main Methods:

  • Investigated protein expression levels of USP30 and MFN2 in IIR models.
  • Utilized overexpression of USP30 and MFN2, and knockdown of MFN2.
  • Assessed mitochondrial function and endoplasmic reticulum stress markers.

Main Results:

  • IIR was found to reduce the expression of USP30 and MFN2.
  • Overexpression of USP30 increased MFN2 stability via deubiquitination, alleviating IIR-induced damage.
  • Overexpression of MFN2 restored mitochondrial function and reduced endoplasmic reticulum stress in IIR, while MFN2 knockdown diminished USP30's protective effects.

Conclusions:

  • USP30 alleviates IIR-induced endoplasmic reticulum stress and mitochondrial dysfunction by reducing MFN2 ubiquitination.
  • USP30 enhances MFN2 stability, protecting the mitochondria-associated endoplasmic reticulum (MAMs).
  • USP30 regulation presents a promising therapeutic strategy for mitigating intestinal ischemia-reperfusion injury.